304results about How to "Relief of clinical symptoms" patented technology

The invention provides a Chinese herbal preparation for treating posirasis, which adopts 58 raw medicinal materials such as astragalus root, suberect spatholobus stem, Job stears, glabrous greenbrierrhizome, spreading hedyotis herb, barbed skullcap herb, motherwort herb and the like to manufacture oral agent and abrasive cleaner. The manufacturing method of the invention is as follows: 1. manufacturing by using the above raw material medicines into water-decocted liquid according to the conventional method; 2. manufacturing by using the water-decocted liquid which is manufactured in step 1 into oral liquid according to the conventional method; 3. drying, grinding and sieving the water-decocted liquid which is manufactured in step 1, and taking the throughs as powder; and 4. manufacturinginto powder tablets, granular formulation, medicinal granules or capsules by utilizing step 3 according to the conventional method. The powder and the abrasive cleaner can be manufactured by the following steps: 1. grinding the above raw material medicines; 2. sieving; and 3. taking the throughs, disinfecting and sterilizing to obtain the powder. The invention has high cure rate, low recurrence rate, can treat the primary and the secondary aspects at the same time, is safe and reliable, and can strengthen the autoimmunity. The invention mainly treats various types of posirasis, can treat neurodermatitis, comedo, acne and eczema concurrently, and has effects on lupus erythematosus, syphilis, lepra and skin cancer.

A pharmaceutically acceptable carrier for ophthalmic compositions useful in treating or alleviating the symptoms of dry eye syndrome, elevated intra-ocular pressure, age-related maculopathy or age-related macular degeneration.

Disclosed is an anticancer tumour extinguishing toxin expelling decoction, which is prepared from Chinese medicinal herbs including toad, Eupolyphaga Sinensis Walker, leeches, cantharis, house lizard, astragalus root, gen-seng, ganoderma lucidum, notoginseng, white atractylodes rhizome, burred tuber, zedoary, peach kernels, safflower and Oldenlandis.

The invention relates to an oral liquid for healing hemiplegia, which is prepared from the following raw materials in parts by weight: 90-180 of raw milkvetch root, 3-15 of Chinese angelica, 3-10 of red paeony root, 3-10 of earthworm, 3-10 of rhizome chuanxiong, 3-10 of peach seed, 3-10 of safflower, 5-15 of pueraria root, 2-5 of pseudo-ginseng, 8-15 of tall gastrodia tuber and 5-20 of zaocys dhumnade. Aiming at the etiology and pathogenesis of hemiplegia, the oral liquid is formed by scientifically matching primary components with secondary components in multiple factors and has the efficacies of tonifying qi and blood, promoting blood circulation and removing obstruction in channels, stanching, dispersing pathogenic wind, and the like. The oral liquid has the advantages of easily-obtained raw material, no toxic side effect and favorable rehabilitation effect, is prepared by a simple process and is convenient to take. By clinically implementing the test administration treatment on 863 hemiplegic patients suffering from cerebrovascular accident (stroke) for years, the oral liquid has remarkable curative effect for all the patients receiving the test administration treatment, wherein 820 patients are clinically healed; and the effective rate for treatment reaches 100 percent and the cure rate reaches 95 percent.

The invention discloses a Chinese traditional medicine combination for treating mastosis and a preparing method. The Chinese traditional medicine combination is prepared by dandelion, bupleurum root, angelica, nutagrass flatsedge rhizome (vinegar bake), radix salviae miltiorrhizae, root of herbaceous peony (fried), seed of cowherb, red peony root, bighead atractylodes rhizome (fried). The Chinese traditional medicine combination has excellent function of clearing the liver and enriching the blood, regulating vital energy and dispelling melancholy without toxicity and side-effect and is adaptable to hypochondriac distress and pain, breast nodule and tenderness, breast pain before menstruation, abnormal menstruation and hyperplasia of mammary glands. Compared with the prior art, the invention has good prescription, high bioavailability and remarkable therapeutic effects.

The invention discloses an antagonistic drug against replication of a porcine reproductive and respiratory syndrome virus (PRRSV) and application of the antagonistic drug. A virus infection test is adopted, and Xanthohumol (Xn), the antagonistic drug of the PRRSV, is discovered for the first time from a natural medicine library with 386 plant sources. The drug can effectively inhibit PRRSV replication in both Marc-145 and PAM cells, five xanthohumol derivatives with different molecular structures are artificially synthesized, and the viral infection test further finds that the inhibition effect to virus replication by drug derivative Xn-4 is highest in vitro; and test results of artificial infection and drug therapy in piglets show that the Xn-4 can effectively inhibit PRRSV viremia, relieves clinical symptoms of infected pigs, and significantly reduces pulmonary inflammation and pathological damage. Combined with the results, it is proved that the antagonistic drug has important preventive and therapeutic effects to a porcine reproductive and respiratory syndrome, and has important application prospects.

The invention relates to the use of agents that bind the complement protein C5 in the treatment of diseases associated with inappropriate complement activation, and in particular in the treatment of respiratory disorders.

The present invention relates to the field of CAdV vector vaccines, and especially to promoters suitable to express target antigens from such vector vaccines. Disclosed and claimed are recombinant canine adenoviruses, methods of making them, uses for them (including in immunological, immunogenic, vaccine or therapeutic compositions, or, as a vector for cloning, replicating or expressing DNA and methods of using the compositions and vector), expression products from them, and uses for the expression products. Additionally, disclosed and claimed are truncated EHV4 promoters, expression cassettes containing the promoters, and recombinant viruses and plasmids containing the promoters or expression cassettes.

The invention relates to Chinese medicinal composition for treating gynaecology disease, which is prepared from sophora flavescens, thlaspi arvense linn, whiteflower patrinia herb, heydyotis, corydalis tuber, radix paeoniae rubrathe, fructus toosendan, Chinese angelica, combined spicebush and milettia reticulate. The Chinese medicinal composition is used for releasing heat, eliminating dampness, regulating menstruation and stopping leucorrhea, and has excellent effect for treatment of chronic uterine neck and chronic pelvic inflammatory disease due to syndrome of dampness-heat in lower jiao.

The present invention relates to a pharmaceutical composition and health supplement for preventing or treating atopic dermatitis, the composition and supplement having as active ingredients extract of a galenical mixture including sophora root, licorice, lonicer aflower, Korean angelica root, Korean aralia root, saussurea root, seselos radix, zizyphus spinosi, Houttuynia cordata, forsythia fruit, lappa fruit, Epimedium koreanum Nakai, ginseng, lithospermum, oleoresin, cnidium, scorophulariae radix, and reynoutria, or lactobacillus fermentation of the galenical extract prepared by inoculating lactobacillus to the galenical extract and fermenting same. The galenical extract or the galenical extract fermentation of the present invention achieves reduced scratching, decreases clinical features of atopic symptoms such as erythema, itchiness and dry skin, edema and hematoma, erosion, and lichenification, and reduces IgE concentration in blood, which is related to exogenous atopic dermatitis, in laboratory animal models of atopic dermatitis, and is thereby, useful for preventing or treating atopic dermatitis.

The invention discloses a pill inducing diuresis and reducing edema for treating gonarthromeningitis. In parts by weight, the pill inducing diuresis and reducing edema consists of fried astragalus, atractylodes rhizome, poria cocos, semen coicis, powder yam rhizome, plantain seed, rhizome alismatis, leonurus, radix rehmanniae recen, golden cypress, honeysuckle stem, dogwood, rhizome sparganii and curcuma zedoary. The pill is prepared by grinding and evenly mixing the raw materials, adding microcrystalline cellulose and water and mixing evenly. By treating gonarthromeningitis with the pill, the treatment curative effect is remarkable, the treatment course is short, the cost is low, and toxic and side effect is avoided. The effective rate of the curative effect is as high as 95%.

The invention discloses a traditional Chinese medicine composition for treating three-high diseases and a preparation method therefor. The traditional Chinese medicine composition comprises the following raw materials: red sage root, pseudo-ginseng, radix polygoni multiflori, haws, wolfberries and cassia seeds. The traditional Chinese medicine composition can be prepared into any common oral administration dosage form or health product, has functions of promoting blood circulation to remove blood stasis, benefiting liver and kidney, raising internal organ functions and promoting metabolism, and can lower blood glucose and blood fat and inhibit blood medicine rise. The traditional Chinese medicine composition has substantial curative effects of treating hypertension, hyperlipidemia and diabetes, the total effective rate for three-high diseases can reach more than 90% and no rebound is generated after the medicine is stopped. The Traditional Chinese medicine composition has minimal side effects and can be taken for a long time.

The invention discloses an ankylosing spondylitis microbial marker, which is formed by the following microbes: Actinomyces sp. ICM47, Bifidobacterium breve, Bifidobacterium sp.12_1_47 BFAA, Bifidobacterium longum, Collinsella aerofaciens, Bifidobacterium bifidum and Bifidobacterium pseudocatenulatum. The invention also discloses a method and a device for determining an individual condition by utilizing the ankylosing spondylitis microbial marker. Compared with a healthy group, the ankylosing spondylitis microbial marker is obviously enriched in an ankylosing spondylitis patient population, and can be used as a distinction marker of the healthy population and the ankylosing spondylitis patient population.